The Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longitudinal Clinical Outcomes, with a Long-Term Goal of Reaching 1 Million Genomes CHICAGO --(BUSINESS WIRE)--Sep. 11, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a
The Initiative Will Pioneer an AI Agent That Functions as an Extension of the Clinician Team, Capable of Delivering and Coordinating Cardiovascular Care Without Direct Human Intervention CHICAGO --(BUSINESS WIRE)--Sep. 9, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been
CHICAGO --(BUSINESS WIRE)--Sep. 4, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.
ECG-PH clearance adds pulmonary hypertension to Tempus’ FDA -cleared AI products for atrial fibrillation and low ejection fraction CHICAGO --(BUSINESS WIRE)--Aug. 24, 2026-- Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S.
Tempus' multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis CHICAGO --(BUSINESS WIRE)--Aug. 4, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to
CHICAGO --(BUSINESS WIRE)--Jul. 30, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. “Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder
CHICAGO --(BUSINESS WIRE)--Jul. 22, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the cancer care continuum and accelerates access to industry-leading technology
Findings from the multi-center Articulate Pro study show Paige Prostate improves diagnostic consistency, accelerates turnaround times, and reduces laboratory workloads CHICAGO --(BUSINESS WIRE)--Jul. 16, 2026-- Tempus, a technology company leading the adoption of AI to advance precision medicine,
CHICAGO --(BUSINESS WIRE)--Jul. 9, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026.
